Klaria Pharma Holding
0.446
SEK
-0.67 %
KLAR
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
-0.67%
-6.89%
-25.67%
0%
+1.36%
-3.46%
+31.56%
-92.64%
-92.2%
-90.49%
www.klaria.com/sv/investerare
Klaria Pharma Holding operates in the pharmaceutical industry. The business is focused on developing and commercializing solutions in the therapy areas of migraine and cancer-related pain. The technology is based on the company's drug-delivery platform, where the product consists of the alginate-based polymer film. The film attaches to the patient's oral mucosa, which enables the distribution of pharmaceuticals in the body. The head office is located in Uppsala.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
KLAR
Daily low / high price
0.354 / 0.448
SEK
Market cap
64.56M SEK
Turnover
86.55K SEK
Volume
214K
Financial calendar
Interim report
2024-11-21
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Ålandsbanken | 6.7 % | 6.7 % |
| Skandinaviska Enskilda Banken | 4.3 % | 4.3 % |
| Djerdu Invest AB | 3.8 % | 3.8 % |
| Jack Weil | 3.8 % | 3.8 % |
| Promenaden Invest AB | 3.8 % | 3.8 % |
| Fredrik Hübinette | 3.6 % | 3.6 % |
| Buntel AB | 3.5 % | 3.5 % |
| Munkekullen Förvaltnings AB | 3.5 % | 3.5 % |
| Sven-Olov Hjälmstad | 3.5 % | 3.5 % |
| Banque Pictet & CIE | 3.3 % | 3.3 % |
ShowingAll content types
Redeye: Klaria Pharma Q2 - Defining Chapter Approaches
Klaria Pharma Holding AB: Klaria Interim Report Q2 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools